Treatment Practices for Infantile Epileptic Spasms Syndrome: Consensus and Variation in Major Pediatric Epilepsy Centers
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Treatment protocols for infantile epileptic spasms syndrome (IESS) show variation despite consensus on initial therapies. Research is needed to standardize treatment for better outcomes in pediatric epilepsy.
Area Of Science
- Pediatric Neurology
- Epileptology
- Clinical Research
Background
- Infantile epileptic spasms syndrome (IESS) is a severe developmental and epileptic encephalopathy requiring prompt treatment.
- Established first-line therapies include adrenocorticotrophic hormone, prednisolone, and vigabatrin.
- Hypothesized variability in the implementation of these IESS treatment protocols across medical centers.
Purpose Of The Study
- To investigate and compare the treatment pathways for infantile epileptic spasms syndrome (IESS) across different US epilepsy centers.
- To identify variations in the application of established and alternative therapies for IESS.
- To understand the influence of factors like insurance barriers on treatment protocols.
Main Methods
- A REDCap survey was distributed to 75 US epilepsy centers by the Pediatric Epilepsy Research Consortium.
- Treatment pathway characteristics were extracted and compared.
- Standard therapy regimens were predefined before data collection.
Main Results
- Thirty-six centers participated, with 89% having IESS treatment pathways, often influenced by insurance barriers (72%).
- Most protocols (88%) recommended a standard course for new-onset IESS, with 63% favoring sequential hormonal therapy/vigabatrin and 17% combination therapy.
- Approaches to side-effect mitigation varied, with common mention of GI prophylaxis and BP control; ketogenic diet and epilepsy surgery were also noted.
Conclusions
- Broad consensus exists on first and second-line therapies for IESS, but significant variability is observed in sequential vs. combination therapy, third-line treatments, and adverse event monitoring.
- These findings highlight the need for further research to address key questions regarding treatment strategies.
- The ultimate goal is to develop a standardized, consensus-driven treatment protocol for IESS to optimize patient outcomes.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Focal aware seizures: In these seizures, the person remains conscious...
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
Spasmolytic agents are drugs used to alleviate muscle spasms and spasticity. They can be categorized into different chemical groups based on their mechanisms of action. Centrally acting spasmolytics primarily affect the spinal cord, while others directly target skeletal muscle cells.
A major class of centrally acting spasmolytics is the α2-agonist, such as tizanidine. These drugs bind to α2-adrenoceptors, inhibiting the release of the excitatory neurotransmitter glutamate. They also...
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...